QPT Quest PharmaTech Inc.
Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Quest PharmaTech (CVE: QPT)
›
Quest PharmaTech (CVE: QPT) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0200 CAD on 18 November 2026, down 50.0% over 52 weeks. Its 52-week range is 0.0200 CAD to 0.0500 CAD, and it trades at the bottom of that range.
Its market capitalisation is 3.38M CAD.
Quest PharmaTech reports return on equity of 18.9% and an operating margin of 0.0%.
Its debt exceeds its cash by 917.15K CAD, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 31 May 2027.